See more : Birmingham Sports Holdings Limited (2309.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Enfusion, Inc. (ENFN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Enfusion, Inc., a leading company in the Software – Application industry within the Technology sector.
- MonotaRO Co., Ltd. (MONOF) Income Statement Analysis – Financial Results
- Time Technoplast Limited (TIMETECHNO.BO) Income Statement Analysis – Financial Results
- Grand Parade Investments Limited (GPL.JO) Income Statement Analysis – Financial Results
- Identiv, Inc. (INVE) Income Statement Analysis – Financial Results
- Universal Store Holdings Limited (UNI.AX) Income Statement Analysis – Financial Results
Enfusion, Inc. (ENFN)
About Enfusion, Inc.
Enfusion, Inc. provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. It provides portfolio management system, which generates a real-time investment book of record that consists of valuation and risk tools that allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and order and execution management system that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines. The company also offers accounting/general ledger system, a real-time accounting book of record for chief financial officers, chief operating officers, accountants, and operations teams; Enfusion analytics system, which enables CIOs, portfolio managers, traders, and analysts to analyze portfolios through time horizons and automate customized visualized reports for internal and external stakeholders; and technology-powered and managed services. Enfusion Inc. was incorporated in 2021 and is headquartered in Chicago, Illinois.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
---|---|---|---|---|---|
Revenue | 174.54M | 150.35M | 111.70M | 79.57M | 59.03M |
Cost of Revenue | 57.64M | 47.10M | 31.85M | 21.36M | 16.96M |
Gross Profit | 116.89M | 103.25M | 79.86M | 58.21M | 42.07M |
Gross Profit Ratio | 66.97% | 68.67% | 71.49% | 73.16% | 71.27% |
Research & Development | 19.89M | 17.16M | 153.40M | 6.32M | 4.15M |
General & Administrative | 64.64M | 68.76M | 150.61M | 35.89M | 16.63M |
Selling & Marketing | 20.42M | 29.29M | 51.73M | 9.93M | 7.43M |
SG&A | 85.05M | 98.05M | 202.34M | 45.82M | 24.05M |
Other Expenses | 0.00 | -638.00K | -1.19M | 82.00K | -3.00K |
Operating Expenses | 104.95M | 115.21M | 355.74M | 52.13M | 28.20M |
Cost & Expenses | 162.59M | 162.31M | 387.58M | 73.49M | 45.16M |
Interest Income | 0.00 | 413.00K | 4.59M | 1.66M | 724.00K |
Interest Expense | 0.00 | 413.00K | 4.59M | 1.66M | 724.00K |
Depreciation & Amortization | 9.99M | 6.60M | 3.98M | 2.29M | 1.16M |
EBITDA | 21.94M | -5.62M | -271.91M | 8.37M | 15.02M |
EBITDA Ratio | 12.57% | -3.74% | -244.49% | 10.62% | 25.45% |
Operating Income | 11.95M | -11.96M | -275.88M | 6.07M | 13.87M |
Operating Income Ratio | 6.85% | -7.96% | -246.99% | 7.63% | 23.50% |
Total Other Income/Expenses | -464.00K | -225.00K | -5.78M | -1.58M | -727.00K |
Income Before Tax | 11.48M | -12.19M | -281.66M | 4.49M | 13.14M |
Income Before Tax Ratio | 6.58% | -8.11% | -252.16% | 5.65% | 22.26% |
Income Tax Expense | 2.23M | 1.07M | 579.00K | 433.00K | 486.00K |
Net Income | 6.03M | -13.26M | -282.24M | 4.06M | 12.66M |
Net Income Ratio | 3.45% | -8.82% | -252.68% | 5.10% | 21.44% |
EPS | 0.10 | -0.16 | -4.30 | 0.04 | 0.11 |
EPS Diluted | 0.07 | -0.16 | -4.30 | 0.04 | 0.11 |
Weighted Avg Shares Out | 88.20M | 85.39M | 65.58M | 113.05M | 113.05M |
Weighted Avg Shares Out (Dil) | 129.43M | 85.39M | 65.58M | 113.05M | 113.05M |
ENFN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Enfusion, Inc. and Encourages Stockholders to Contact the Firm!
Investors Who Lost Money In Enfusion Inc Invited To Join Securities Fraud Investigation Led By The Schall Law Firm
ENFN STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Enfusion, Inc. and Encourages Shareholders to Contact the Firm!
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Enfusion, Inc. - ENFN
Enfusion Inc Shareholders Invited To Participate In Securities Fraud Investigation Led By The Schall Law Firm
Enfusion Inc Investors Encouraged To Join Securities Fraud Investigation Led By The Schall Law Firm
Levi & Korsinsky Reminds Shareholders of an Investigation into Enfusion, Inc. (ENFN) Regarding Potential Securities Fraud Allegations
ENFN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Enfusion, Inc. and Encourages Shareholders to Contact the Firm!
Investors Invited To Join The Securities Fraud Investigation Of Enfusion, Inc. By The Schall Law Firm
ATTENTION ENFN SHAREHOLDERS: Investors who lost money on Enfusion, Inc. are urged to contact Levi & Korsinsky about an ongoing investigation
Source: https://incomestatements.info
Category: Stock Reports